TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Respiratory Resistance Training on Sleep Quality in Persons With Spinal Cord Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* tetraplegia~* quadriplegia~Exclusion Criteria:~* NA

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Powerlung Performer (Type: EXPERIMENTAL): The arm will receive the lung trainer device to use for 10 weeks
- Control (Type: NO_INTERVENTION): Control. This arm will not receive any device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treating Multiple Sclerosis With Sirolimus, an Immune System Suppressor

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Relapsing-remitting MS~* Evidence of demyelination on magnetic resonance imaging (MRI) scan~* Expanded Disability Status Scale (EDSS) score between 0 and 6~* Nonresponsive to beta-interferon or Glatiramer acetate therapy~* Discontinuation of beta-interferon or Glatiramer acetate therapy within 1 month prior to study entry~* Willing to use acceptable methods of contraception~Exclusion Criteria:~* Primary progressive MS~* Prior treatment with immunosuppressants~* Steroid therapy within 1 month prior to study entry~* Evidence of active infection or cancer~* Heart or hematologic dysfunction~* High levels of lipids in the blood~* Use of lipid-lowering agents~* History of cirrhosis or liver disease requiring treatment~* History of hepatitis B or C~* Active cytomegalovirus infection~* Kidney disease requiring treatment~* Active lung disease~* Diabetes~* Hyperthyroidism~* HIV infection~* Tuberculosis~* History of alcohol or drug abuse within 6 months prior to study entry~* Claustrophobia or inability to undergo MRI~* Pregnancy or breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 58 Years
- Healthy Volunteers: f

Study Arms:
- sirolimus (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Multicenter Study of the Avenue L Interbody Spinal Fusion System Using VerteBRIDGE Plating and Posterior Fixation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be candidates for on-label use of the Avenue L device (have degenerative disc disease, use only at one or two contiguous levels, posterior fixation must be used, autograft must be used in the interbody cage)~* Subject must be skeletally mature at the time of surgery, i.e. the subject must be at least 21 years of age at the time of surgery~* Subject should have had a minimum of 6 months of non-operative treatment prior to surgery~* The placement of the Avenue L device must be a primary surgery~* Subject must be willing to sign the consent form and be able to return for all follow up visits.~Exclusion Criteria:~* Subject must not have had prior surgery at the operative level(s)~* Subject is known to have substance or alcohol addictions~* Subject has lateral curvature of the spine (scoliosis, all types)~* Subject is a prisoner~* Subject is pregnant~* Subject has an active infection or sepsis at the time of surgery~* Subject has any neuromuscular disorder that would preclude accurate neurologic evaluations

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Operated Subjects (Type: None): Subjects scheduled to receive an Avenue® L Interbody Fusion System (LDR Spine) for fusion of the lumbar spine from L2-S1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Functional Lung Avoidance for Individualized Radiotherapy (FLAIR): A Randomized, Double-Blind Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* Willing to provide informed consent~* ECOG performance status 0-2~* Histologically confirmed non-small cell lung carcinoma~* Locally advanced Stage IIIA or IIIB lung carcinoma according to AJCC 7th edition~* History of at least 10-pack-years of smoking~* Not undergoing surgical resection~* Assessment by medical oncologist and radiation oncologist, with adequate bone marrow, hepatic and renal function for administration of platinum-based chemotherapy~Exclusion Criteria:~* Contraindications to MRI~* Serious medical comorbidities (such as unstable angina, sepsis) or other contraindications to radiotherapy or chemotherapy~* Prior history of lung cancer within 5 years~* Prior thoracic radiation at any time~* Metastatic disease. Patients who present with oligometastatic disease where all metastases have been ablated (with surgery or radiotherapy) are candidates if they are receiving chemoradiotherapy to the thoracic disease with curative intent.~* Inability to attend full course of radiotherapy or follow-up visits~* Pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard Arm (Type: ACTIVE_COMPARATOR): Standard platinum-based chemoradiotherapy, total radiation dose 60 Gy in 30 fractions
- Experimental Arm (Type: EXPERIMENTAL): Functional-lung avoidance radiotherapy, total dose 60 Gy in 30 fractions, with concurrent platinum-based chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Nasacort in Chronic Non Allergic and Non Infectious Rhinitis in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patient presenting with Chronic Non Allergic and Non Infectious Rhinitis capable of benefiting from corticosteroid therapy administered via the nasal route.~* patient with chronic rhinitis of minimum duration 12 weeks, whether or not consecutive, per year.~* patient with Non Allergic Rhinitis confirmed by negative phadiatop test.~* patient presenting a mean global score for the 5 symptoms \>= 5 (nasal obstruction, rhinorrhea, disturbance of sense of smell, sneezing, facial heaviness), or mean score for the 3 main symptoms (nasal obstruction, rhinorrhea, disturbance of sense of smell) \>= 5 (mean for 7 days prior to visit V0).~* patient presenting an inflammation score at anterior rhinoscopy or nasal endoscopy \>= 4.~Exclusion Criteria:~* patient presenting a nasal polyp~* patient presenting a severe septal deviation which would interfere with insertion of the nasal spray~* patient presenting a nasal cavity tumor~* patient presenting a sinus infection~* patient presenting a history of endonasal surgery~* patient presenting a chronic rhinitis of extrinsic origin (drug-related or food-related rhinitis) or intrinsic origin (hormonal rhinitis, positional rhinitis,atrophic rhinitis, ...)~* patient on a program of intensive sports training~* patient presenting with : cystic fibrosis, pulmonary mycosis, necrotising vascularitis, immotile cilia syndrome, ....~* patient presenting with known immunosuppression, lymphoma~* patient presenting with a known cardiovascular, neurological or other medically significant illness~* patient presenting with known renal failure, with known glaucoma, with known drug addiction~* current antibiotic therapy~* corticosteroids administered in the two months prior to admission~* patient presenting problems of haemostasis (epistaxis), ophthalmic and/or oro-bucco-nasal herpetic infection.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Phase 2 Study Whole Brain Radiation Therapy With Simultaneous Integrated Boost for Patients With Brain Metastases

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Age ≥ 18 at time of consent.~2. Ability to provide written informed consent and HIPAA authorization.~3. Pathological diagnosis of any solid tumor histology (from any site in the body).~4. Pathological or clinical (i.e., by imaging) diagnosis of brain metastatic tumor lesions.~5. Total volume of lesions ≤ 30 cm3.~6. Maximum volume of largest lesion ≤ 5 cm3.~   a. This volume limit would be equivalent to a largest diameter of about 2.1 cm, assuming a perfect sphere.~7. Not a candidate for or eligible for but refused Gamma Knife radiosurgery.~Exclusion Criteria~1. Previous radiation to the brain, including WBRT or brain radiosurgery.~2. Life expectancy \< 6 months (as estimated per current ds-GPA).~3. For histologies not included in the ds-GPA publications or otherwise noted online at brainmetgpa.com, the PI will use either published or validated data, or the PI's best clinical judgment to determine the patient's expected survival.~4. Inability to comply with treatment per investigator discretion.~5. Inability to complete neurocognitive assessments per investigator discretion.~Of note, tumor lesion number is not an inclusion or exclusion criteria as we are using volume-based criteria instead.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A (Type: EXPERIMENTAL): Standard PCI dose
- Cohort B (Type: EXPERIMENTAL): Low PCI dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Involuntary Memories Investigation in Schizophrenia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* - for patients only~* male or female~* age limits : 18-55 years old~* under the protection of health insurance~* who have signed up the consent form~* schizophrenia or schizo-affective disorder according to the DSM-5 criteria (APA, 2013).~* clinically stable for at least 2 months~* patients under guardianship or curatorship need agreement of their legal representative~* informed of the results of prior medical examination for controls only~* male or female~* age limits : 18-55 years old~* under the protection of health insurance~* who have sign up the consent form~* recruited from the general population and matched on gender, age years of schooling~* no psychiatric history (DSM-5)~Exclusion Criteria:~* for both patients and controls~* current severe or unstable somatic illness~* neurological history (brain injury \> 15 minutes loss of consciousness , epilepsia, brain surgery...)~* current substance use disorder (DSM-5)~* current major depressive disorder (CDSS,BDI, HDRS)~* mental retardation (IQ \< 70, WAIS-4, f-NART)~* history of general anesthesia 3 months prior to the experiment~* pregnancy declared by the subject~* breast feeding~* current legal control~* in emergency situation~* included during exclusion period in another experiment~* for controls only~* taking of antipsychotic drugs for the 3 weeks prior to inclusion~* under guardianship or curatorship

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Control group (Type: ACTIVE_COMPARATOR): Control participants without psychiatric nor neurological history
- Patients with Schizophrenia (Type: EXPERIMENTAL): Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Evaluate PF-00915275 In Subjects With Type 2 Diabetes Mellitus For 4-Weeks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~* HbA1c \> 7.5%.~Exclusion Criteria:~* Recent (within the past 12 months) evidence or history of unstable concomitant disease.~* Treatment with any oral hypoglycemic agent within 3 months before enrollment.~* The exception to these criteria is that subjects who are currently taking metformin hydrochloride, in a stable dose (that is no changes in dose) for treatment of their diabetes within the past 3 months or longer of enrollment may participate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Sorbion in the Treatment of Venous Leg Ulcers The Protocol Elements

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* venous leg ulcer~Exclusion Criteria:~* pregnant females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sorbion dressing to venous leg ulcer (Type: EXPERIMENTAL): any venous leg ulcer will receive sorbion dressing weekly for 4 weeks than wound will be assessed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Microscopic Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Microscopic colitis verified with biopsies from the colon~* Symptoms to such an extent that treatment is indicated~* Age \> 17 years~* Informed consent~Exclusion Criteria:~* Previous treatment with any of the investigational drugs~* Patients treated with ketoconazole~* Pregnant and breast-feeding females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Budesonide (Type: EXPERIMENTAL): Budesonide 9mg
- bismuth (Type: EXPERIMENTAL): Bismuth mixture
- Fiber (Type: SHAM_COMPARATOR): Fiber preparation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Weaning From Mechanical Ventilation Using Permissive Hypercarbia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult (\> 18 yo) patients in the intensive care units at the Hershey Medical Center who are on mechanical ventilation~* and whose clinical course permits weaning from mechanical ventilation~* and are felt to have risk factors for difficult weaning. (Risk factors will include patients with rib fractures, pulmonary contusions, obesity (BMI \>30), or history of COPD or other significant lung disease.)~* all patients will have failed (rapid shallow breathing index \>105) a 30 minute spontaneous breathing test.~Exclusion Criteria:~* Overt signs of sepsis including: a temperature \> 38.5F, white blood cell count \> 14000, systolic blood pressure \< 100 mmHg,~* intracranial hypertension (ICP \> 18 or based upon clinical exam and/or history),~* or pulmonary hypertension (by history or PAsys \> 40 mmHg).~* or history of recent(past 6 mos)MI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Handheld ECG Tracking of In-hOspital Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients admitted to the internal medicine department of the University and Hospital Fribourg throughout the study period will be screened for study enrollment.~Exclusion Criteria:~* Patients with known or previously documented atrial fibrillation, patients with a cardiac pacemaker, and implantable cardioverter-defibrillator or intra-cardiac monitoring device will be excluded from the present trial.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zenicor ON (Type: EXPERIMENTAL): Patients allocated to the experimental group will undergo systematic short ECG monitoring
- Zenicor OFF (Type: NO_INTERVENTION): In patients allocated to the control group, usual diagnostic procedures for detection of atrial fibrillation will be employed according to ESC Guidlines.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Zenith(R) Connection Endovascular Covered Stent Clinical Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* An aortoiliac or iliac aneurysm of appropriate size~* Unsuitable distal sealing site for a traditional Zenith® iliac leg graft within the common iliac artery~Exclusion Criteria:~* Less than 18 years of age~* Inability or refusal to give informed consent~* Disease considerations that would compromise patient safety or study outcomes~* Unsuitable arterial anatomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): Treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cacicol20® in Corneal Wound Healing and Nerve Regeneration After Phototherapeutic Keratectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed and dated informed consent,~* Male or female aged ≥ 18 years,~* Patient with recurrent erosions or epithelial dystrophies indicated for treatment by phototherapeutic keratectomy of the anterior cornea~Exclusion Criteria:~* In the affected eye: prior corneal surgery~* In either eye: active ocular infection, glaucoma, or ocular hypertension~* General history judged by the investigator to be incompatible with the study (life-threatening patient condition).~* Known allergic hypersensitivity history to Poly(carboxyMethylGlucoseSulfate) or dextran.~* Inability of patient to understand the study procedures and thus inability to give informed consent.~* Participation in another clinical study within the last 3 months.~* Already included once in this study (can only be included for one treated eye)~Specific exclusion criteria for women~* Known pregnancy (if uncertain pregnancy test will be performed)~* Lactation~* Women of childbearing potential without an effective method of contraception (oral contraceptive, intra-uterine device, subcutaneous contraceptive implant, vaginal ring) or women not hysterectomised, post-menopausal or surgically sterilized

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cacicol20 (Type: EXPERIMENTAL): Instillation of Cacicol20 eye drops after laser corneal surgery. 3 eye drops total, to be given once immediately after surgery, once 2 days after surgery, and a final time 4 days after surgery.
- Placebo (Type: PLACEBO_COMPARATOR): Instillation of placebo eye drops (vehicle missing the active ingredient) after laser corneal surgery. 3 eye drops total, to be given once immediately after surgery, once 2 days after surgery, and a final time 4 days after surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues